AstraZeneca Price Target Raised to GBX 3,500 at Panmure Gordon (AZN)
Equities research analysts at Panmure Gordon increased their target price on shares of AstraZeneca (LON:AZN) from GBX 3,200 ($52.74) to GBX 3,500 ($57.68) in a research note issued to investors on Thursday, StockRatingsNetwork reports. The firm currently has a “sell” rating on the stock. Panmure Gordon’s target price would indicate a potential downside of 8.97% from the company’s current price.
A number of other analysts have also recently weighed in on AZN. Analysts at Credit Suisse reiterated an “underperform” rating on shares of AstraZeneca in a research note to investors on Thursday. They now have a GBX 3,220 ($53.07) price target on the stock. Separately, analysts at Liberum Capital reiterated a “buy” rating on shares of AstraZeneca in a research note to investors on Thursday. They now have a GBX 4,600 ($75.81) price target on the stock. Finally, analysts at Berenberg Bank raised their price target on shares of AstraZeneca from GBX 3,420 ($56.36) to GBX 3,600 ($59.33) in a research note to investors on Wednesday. They now have a “hold” rating on the stock. Twelve equities research analysts have rated the stock with a sell rating, sixteen have given a hold rating and six have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of GBX 3,301.03 ($54.40).
AstraZeneca (LON:AZN) traded up 0.75% during mid-day trading on Thursday, hitting GBX 3874.0002. 2,659,001 shares of the company’s stock traded hands. AstraZeneca has a 1-year low of GBX 2895.00 and a 1-year high of GBX 3886.50. The stock has a 50-day moving average of GBX 3568. and a 200-day moving average of GBX 3323.. The company’s market cap is £48.541 billion.
AstraZeneca PLC (LON:AZN) is a global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.